** Shares of Telix Pharmaceuticals rise 2.3% to a record high of A$26.46
** The biopharma co says its Illuccix, a prostate cancer imaging agent, received European approval
** Says all 18 European Economic Area member states agreed Illuccix should be approved
** Co stock on track for a fifth consecutive session of gains, if current trend holds
** Stock up over 7% YTD including session's moves
(Reporting by Rajasik Mukherjee in Bengaluru)
((Rajasik.Mukherjee@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。